Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Does sickle cell disease increase risk of adverse outcomes following total hip and knee arthroplasty? A nationwide database study
source: The Journal of Arthroplasty
year: 2015
authors: Perfetti DC, Boylan MR, Naziri Q, Khanuja HS, Urban WP
summary/abstract:Sickle cell disease (SCD) is associated with impaired vascular function and progressive vaso-occlusive injury to bones. We used the Nationwide Inpatient Sample to identify all THA and TKA admissions between 1998 and 2010. After controlling for patient age, gender, insurance, race, and comorbidities, the risk of complication among admissions with SCD was 152% higher (P<0.001) for THA and 137% higher (P=0.001) for TKA. Patients with SCD had a length of stay that was 42% longer (P<0.001) for THA and 20% longer for TKA (P<0.001), and hospital charges that were 19% higher (P<0.001) for THA and 16% higher (P=0.001) for TKA. Orthopedic surgeons should counsel potential THA and TKA candidates with SCD of these risks prior to admission.
organization: SUNY Downstate Medical Center, Brooklyn; The Johns Hopkins University, BaltimoreDOI: 10.1016/j.arth.2014.10.035
read more full text
+myBinderRelated Content
-
Novo Nordisk obtains licence for sickle cell disease programNovo Nordisk inked a global licence deal...
-
The FDA Encourages New Treatments for Sickle Cell DiseaseThe FDA continues to work with stakehold...
-
Changes in transcranial doppler flow velocities in children with sickle cell disease: The impact of hydroxyurea ther...Background and Objectives: Hydroxyurea ...
-
Endari reduces pain crises, hospitalizations in sickle cell patients, phase 3 trial showsTreatment with Endari (L-glutamine) le...
-
These patients had sickle-cell disease. Experimental therapies might have cured themScientists have long known what causes s...
-
Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia ...Bioverativ Inc. (NASDAQ: BIVV), a global...
-
Big Jump in Success for Sickle Cell TransplantsDoubling the dose of total-body irradiat...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.